JP6821429B2 - Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 - Google Patents
Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 Download PDFInfo
- Publication number
- JP6821429B2 JP6821429B2 JP2016516851A JP2016516851A JP6821429B2 JP 6821429 B2 JP6821429 B2 JP 6821429B2 JP 2016516851 A JP2016516851 A JP 2016516851A JP 2016516851 A JP2016516851 A JP 2016516851A JP 6821429 B2 JP6821429 B2 JP 6821429B2
- Authority
- JP
- Japan
- Prior art keywords
- pcv2b
- seq
- branched
- residue
- pcv2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 173
- 229960005486 vaccine Drugs 0.000 title description 109
- 241001673668 Porcine circovirus type 2-B Species 0.000 claims description 194
- 241001673669 Porcine circovirus 2 Species 0.000 claims description 178
- 241000700605 Viruses Species 0.000 claims description 144
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 claims description 124
- 101710130262 Probable Vpr-like protein Proteins 0.000 claims description 124
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 229920001184 polypeptide Polymers 0.000 claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 83
- 108091007433 antigens Proteins 0.000 claims description 83
- 150000001413 amino acids Chemical group 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 77
- 239000002671 adjuvant Substances 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 40
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 36
- 239000004472 Lysine Substances 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 claims description 36
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 30
- 229960000310 isoleucine Drugs 0.000 claims description 30
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 30
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 29
- 229960001230 asparagine Drugs 0.000 claims description 29
- 235000009582 asparagine Nutrition 0.000 claims description 29
- 229960002898 threonine Drugs 0.000 claims description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 28
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 28
- 239000004473 Threonine Substances 0.000 claims description 28
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 15
- 241000928435 Porcine circovirus 1 Species 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- 239000004471 Glycine Substances 0.000 claims description 14
- 230000002458 infectious effect Effects 0.000 claims description 14
- 244000052769 pathogen Species 0.000 claims description 12
- 241000204031 Mycoplasma Species 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 9
- 241000960387 Torque teno virus Species 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 241001148534 Brachyspira Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000711493 Porcine respiratory coronavirus Species 0.000 claims description 4
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 241001485053 Suid betaherpesvirus 2 Species 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 230000001850 reproductive effect Effects 0.000 claims description 4
- 208000013223 septicemia Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 239000002435 venom Substances 0.000 claims description 3
- 210000001048 venom Anatomy 0.000 claims description 3
- 231100000611 venom Toxicity 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 74
- 241000282887 Suidae Species 0.000 description 58
- 239000002773 nucleotide Substances 0.000 description 43
- 125000003729 nucleotide group Chemical group 0.000 description 43
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 41
- 241000282898 Sus scrofa Species 0.000 description 34
- 238000011282 treatment Methods 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 206010058874 Viraemia Diseases 0.000 description 28
- 230000002550 fecal effect Effects 0.000 description 28
- 239000002609 medium Substances 0.000 description 27
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 26
- 241000701447 unidentified baculovirus Species 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000002779 inactivation Effects 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 23
- 229940068196 placebo Drugs 0.000 description 20
- 239000000902 placebo Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 101150009852 ORF2 gene Proteins 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000013603 viral vector Substances 0.000 description 14
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 13
- 101710113540 ORF2 protein Proteins 0.000 description 13
- 101710090523 Putative movement protein Proteins 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 230000029142 excretion Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 208000001726 Classical Swine Fever Diseases 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000000415 inactivating effect Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 102000004407 Lactalbumin Human genes 0.000 description 6
- 108090000942 Lactalbumin Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000202347 Porcine circovirus Species 0.000 description 6
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000011888 autopsy Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 241000702619 Porcine parvovirus Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012888 bovine serum Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000007485 viral shedding Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 241000710777 Classical swine fever virus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229940024545 aluminum hydroxide Drugs 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940087586 escherichia coli antigen Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000037824 growth disorder Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 238000013081 phylogenetic analysis Methods 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 241001533399 Circoviridae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001148567 Lawsonia intracellularis Species 0.000 description 2
- 241000700639 Parapoxvirus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 231100000171 higher toxicity Toxicity 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000036435 stunted growth Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PQNPQSAJMYMILD-UHFFFAOYSA-N 2-[1-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(C(CC)N(CCO)CCO)CCCCCCCCCCCCCCCCCC PQNPQSAJMYMILD-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241001581234 Histophilus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001469654 Lawsonia <weevil> Species 0.000 description 1
- 241000702489 Maize streak virus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027256 Meningitis streptococcal Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- -1 dextran sulfate Chemical compound 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940031689 heterologous vaccine Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000001881 scanning electron acoustic microscopy Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000001739 streptococcal meningitis Diseases 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10041—Use of virus, viral particle or viral elements as a vector
- C12N2750/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882289P | 2013-09-25 | 2013-09-25 | |
| US61/882,289 | 2013-09-25 | ||
| PCT/US2014/057190 WO2015048115A1 (en) | 2013-09-25 | 2014-09-24 | Pcv2b divergent vaccine composition and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126715A Division JP2019206541A (ja) | 2013-09-25 | 2019-07-08 | Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531854A JP2016531854A (ja) | 2016-10-13 |
| JP2016531854A5 JP2016531854A5 (enExample) | 2017-10-19 |
| JP6821429B2 true JP6821429B2 (ja) | 2021-01-27 |
Family
ID=51688446
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516851A Active JP6821429B2 (ja) | 2013-09-25 | 2014-09-24 | Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 |
| JP2019126715A Pending JP2019206541A (ja) | 2013-09-25 | 2019-07-08 | Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126715A Pending JP2019206541A (ja) | 2013-09-25 | 2019-07-08 | Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9987348B2 (enExample) |
| EP (2) | EP3049106A1 (enExample) |
| JP (2) | JP6821429B2 (enExample) |
| KR (2) | KR102319843B1 (enExample) |
| CN (1) | CN105579060B (enExample) |
| BR (1) | BR112016006192A2 (enExample) |
| CA (1) | CA2925281C (enExample) |
| HK (1) | HK1225645A1 (enExample) |
| MX (1) | MX373669B (enExample) |
| PH (1) | PH12016500473B1 (enExample) |
| RU (1) | RU2662685C2 (enExample) |
| WO (1) | WO2015048115A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2994162T3 (en) | 2013-05-08 | 2021-06-21 | Pharmgate Biologics Inc | Vaccine for pcv2 og mycoplasma |
| RU2662685C2 (ru) * | 2013-09-25 | 2018-07-26 | Зоэтис Сервисиз Ллс | Pcv2b дивергентная вакцинная композиция и способы её применения |
| EA201800494A1 (ru) * | 2016-03-07 | 2019-07-31 | Вирджиния Тех Интеллектуал Пропертис, Инк. | Вакцины против химерного цирковируса свиней типа 2 (pcv2) |
| GB201614799D0 (en) * | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| CN106754980A (zh) * | 2016-12-29 | 2017-05-31 | 福州大学 | Pcv2型衣壳蛋白基因、表达菌株及可溶性表达方法 |
| ES2962449T3 (es) | 2017-10-17 | 2024-03-19 | Intervet Int Bv | Expresión recombinante de la proteína ORF2 del PCV2b en células de insecto |
| JP2021527073A (ja) * | 2018-06-11 | 2021-10-11 | セヴァ サンテ アニマレＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ | ブタサーコウイルスに対するワクチン接種 |
| CN110606873B (zh) * | 2019-09-09 | 2021-05-04 | 武汉科前生物股份有限公司 | 猪圆环病毒2d型与3型Cap蛋白二联亚单位疫苗及其制备方法与应用 |
| KR102769557B1 (ko) * | 2021-11-19 | 2025-02-20 | 주식회사 이노백 | 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도 |
| CN115960259B (zh) * | 2022-10-07 | 2023-11-24 | 浙江大学 | 一种模块化组装双组分纳米颗粒制备方法及其应用 |
| WO2024096648A1 (ko) * | 2022-11-03 | 2024-05-10 | 주식회사 옵티팜 | 신규한 재조합 pcv2d 항원 및 이의 용도 |
| CN117100851A (zh) * | 2023-10-23 | 2023-11-24 | 成都依思康生物科技有限公司 | 一种佐剂、疫苗组合物及其制备方法和应用 |
| US20250332242A1 (en) | 2024-04-30 | 2025-10-30 | Zoetis Services Llc | Porcine endogenous retrovirus (perv)-free porcine circovirus type 2d-based vaccines and methods of use |
| US20250332243A1 (en) | 2024-04-30 | 2025-10-30 | Zoetis Services Llc | Methods of manufacturing porcine endogenous retrovirus (perv) free animal health vaccines |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2262533A (en) | 1939-12-09 | 1941-11-11 | William D Hedge | Water-cooled grate |
| FR964808A (enExample) | 1941-03-20 | 1950-08-25 | ||
| FR2422956A1 (fr) | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
| FR2518755B1 (fr) | 1981-12-23 | 1986-04-11 | Pasteur Institut | Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4567043A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
| US5545412A (en) | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5106733A (en) | 1987-06-25 | 1992-04-21 | Immunex Corporation | Bovine granulocyte-macrophage colony stimulating factor |
| SU1538305A1 (ru) | 1987-07-21 | 1994-12-15 | Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР | Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней |
| US5238662A (en) | 1987-07-31 | 1993-08-24 | Chevron Research Company | Processes for recovering precious metals |
| US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
| DE69027112T2 (de) | 1989-01-23 | 1997-01-09 | Auspharm International Ltd 4Th | Impfstoffzusammensetzung |
| US5811103A (en) | 1989-03-19 | 1998-09-22 | Akzo Nobel N.V. | Hog cholera virus vaccine and diagnostic |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU657907B2 (en) | 1990-05-29 | 1995-03-30 | Wyeth Holdings Corporation | Mycoplasma hyopneumoniae vaccine |
| US5147966A (en) | 1990-07-31 | 1992-09-15 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Polyimide molding powder, coating, adhesive and matrix resin |
| US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| WO1992005255A1 (en) | 1990-09-13 | 1992-04-02 | Commonwealth Scientific And Industrial Research Organisation | Ovine cytokine genes |
| GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
| EP0555366B1 (en) | 1990-11-01 | 2000-06-28 | Iowa State University Research Foundation, Inc. | Bacterial attenuation method and vaccine |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| ES2026827A6 (es) | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino. |
| US5580557A (en) | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
| US6033904A (en) | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
| US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
| US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| CA2139756A1 (en) | 1992-07-08 | 1994-01-20 | Eric M. Bonnem | Use of gm-csf as a vaccine adjuvant |
| CZ289743B6 (cs) | 1993-02-08 | 2002-03-13 | Bayer Corporation | Izolát viru vepřového reprodukčního a respiračního syndromu PRRSV, způsob kultivace PRRSV, tkáňová kultura, způsob přípravy vakcíny a vakcína obsahující PRRSV izolát |
| EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| EP0698245A1 (en) | 1993-05-14 | 1996-02-28 | Mds Health Group Limited | Electronic worksheet system for microbiology testing and reporting |
| EP0702516A4 (en) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | GENETIC IMMUNIZATION WITH CATIONIC LIPIDS |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
| EP0758397B1 (en) | 1994-04-29 | 2005-06-22 | Baxter Healthcare S.A. | Recombinant poxviruses with foreign polynucleotides in essential regions |
| SI0968722T1 (sl) | 1994-05-10 | 2007-10-31 | Wyeth Corp | Izboljĺ ano, modificirano ĺ˝ivo cepivo proti brsv |
| GB2289279B (en) | 1994-05-13 | 1998-09-16 | Iberica Cyanamid | Diagnostic kits and vaccines containing recombinant PRRSV proteins |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| US5788962A (en) | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
| US6043232A (en) | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
| EP0826063A1 (en) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| CN1194001A (zh) | 1995-06-07 | 1998-09-23 | 埃斯库拉普公司 | 鸡贫血症病毒的中和构象表位 |
| US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5795872A (en) | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
| FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
| PT835930E (pt) | 1996-10-09 | 2001-06-29 | Akzo Nobel Nv | Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv) |
| GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| AU1987197A (en) | 1997-03-10 | 1998-09-29 | Heather Lynn Davis | Gene delivery to mucosal epithelium for immunization or therapeutic purpose |
| US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| FR2769322B1 (fr) | 1997-10-03 | 2002-03-08 | Merial Sas | Nouveaux circovirus porcins, vaccins et reactifs de diagnostic |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| FR2769321B1 (fr) | 1997-10-03 | 2001-10-26 | Merial Sas | Nouveaux circovirus porcins, vaccins et reactifs de diagnostics |
| FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
| US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
| US6165493A (en) | 1997-10-22 | 2000-12-26 | New York Blood Center, Inc. | "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections" |
| KR20010032493A (ko) | 1997-11-26 | 2001-04-25 | 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 | 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신 |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
| JP3795751B2 (ja) | 1997-12-11 | 2006-07-12 | ユニバーシティ オブ サスカッチェワン | ブタからの離乳後多全身系消耗症候群ウイルス |
| WO1999045956A1 (en) | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
| US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
| WO2000024428A2 (en) | 1998-10-23 | 2000-05-04 | Heska Corporation | Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| NZ501264A (en) | 1998-12-22 | 2001-09-28 | Pfizer Prod Inc | Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS |
| FR2789695B1 (fr) | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
| US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
| US6179461B1 (en) | 1999-09-03 | 2001-01-30 | Davis-Standard Corporation | Extruder screw |
| US6139179A (en) | 1999-09-03 | 2000-10-31 | Davis-Standard Corporation | Extruder screw having multi-channeled barrier section |
| WO2001017556A1 (fr) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Préparations vaccinales administrables par les muqueuses |
| CA2410229A1 (en) | 2000-06-15 | 2001-12-20 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
| DE10044648A1 (de) | 2000-09-08 | 2002-03-21 | Aventis Behring Gmbh | Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material |
| US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
| CA2442135C (en) | 2001-03-27 | 2008-08-19 | University Of Saskatchewan | Methods to culture circovirus |
| AUPR567401A0 (en) | 2001-06-14 | 2001-07-12 | University Of Melbourne, The | Circovirus vaccines |
| US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| US20030215455A1 (en) | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
| US7419806B2 (en) | 2002-06-28 | 2008-09-02 | Iowa State University Research Foundation, Inc. | Immunogenic Mycoplasma hyopneumoniae polypeptides |
| UA87665C2 (ru) | 2003-07-25 | 2009-08-10 | Берингер Ингельхайм Ветмедика, Инк. | Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis |
| US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
| US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
| ATE462445T1 (de) | 2005-01-13 | 2010-04-15 | Boehringer Ingelheim Vetmed | Prrs-impfstoffe |
| MX2007012786A (es) | 2005-04-13 | 2008-01-11 | Merial Ltd | Ensayo para produccion de circovirus porcino. |
| DK1926496T3 (da) * | 2005-09-09 | 2013-09-30 | Intervet Int Bv | PCV-2-vaccine |
| EP3320919B1 (en) * | 2005-12-29 | 2020-05-27 | Boehringer Ingelheim Animal Health USA Inc. | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
| DK2371383T3 (en) | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs |
| AU2007333857B2 (en) * | 2006-12-15 | 2014-05-15 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of pigs with PCV2 antigen |
| US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| US20090162398A1 (en) | 2007-12-21 | 2009-06-25 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| US8703468B2 (en) | 2008-11-28 | 2014-04-22 | Ceva Sante Animale | Porcine circovirus type 2B isolate and uses thereof |
| HRP20200258T1 (hr) * | 2010-03-16 | 2020-09-04 | Virginia Tech Intellectual Properties Inc | Živo atenuirano himerno cjepivo protiv svinjskog cirkovirusa |
| CN102296089B (zh) * | 2011-04-20 | 2013-09-11 | 中国兽医药品监察所 | 高效制备猪圆环病毒2型空衣壳粒子的方法 |
| CA2837125A1 (en) * | 2011-05-27 | 2012-12-06 | Sinovet (Beijing) Biotechnology Co.,Ltd | Combined vaccines for prevention of porcine virus infections |
| CN103122352B (zh) * | 2012-09-27 | 2015-02-11 | 华中农业大学 | 一种猪圆环病毒2型重组杆状病毒及制备方法和应用 |
| EP3035958B1 (en) | 2013-08-23 | 2022-10-26 | Boehringer Ingelheim Animal Health USA Inc. | Porcine circovirus type 2 (pcv2) subunit vaccine |
| RU2662685C2 (ru) * | 2013-09-25 | 2018-07-26 | Зоэтис Сервисиз Ллс | Pcv2b дивергентная вакцинная композиция и способы её применения |
-
2014
- 2014-09-24 RU RU2016110430A patent/RU2662685C2/ru active
- 2014-09-24 HK HK16114102.8A patent/HK1225645A1/zh unknown
- 2014-09-24 KR KR1020187009981A patent/KR102319843B1/ko active Active
- 2014-09-24 MX MX2016003855A patent/MX373669B/es active IP Right Grant
- 2014-09-24 EP EP14782029.4A patent/EP3049106A1/en not_active Ceased
- 2014-09-24 KR KR1020167007769A patent/KR20160046879A/ko not_active Ceased
- 2014-09-24 JP JP2016516851A patent/JP6821429B2/ja active Active
- 2014-09-24 EP EP22171259.9A patent/EP4091629A1/en active Pending
- 2014-09-24 CA CA2925281A patent/CA2925281C/en active Active
- 2014-09-24 US US14/917,620 patent/US9987348B2/en active Active
- 2014-09-24 WO PCT/US2014/057190 patent/WO2015048115A1/en not_active Ceased
- 2014-09-24 CN CN201480052946.0A patent/CN105579060B/zh active Active
- 2014-09-24 BR BR112016006192A patent/BR112016006192A2/pt not_active Application Discontinuation
-
2016
- 2016-03-10 PH PH12016500473A patent/PH12016500473B1/en unknown
-
2019
- 2019-07-08 JP JP2019126715A patent/JP2019206541A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9987348B2 (en) | 2018-06-05 |
| JP2016531854A (ja) | 2016-10-13 |
| CN105579060B (zh) | 2021-03-16 |
| US20160220658A1 (en) | 2016-08-04 |
| CN105579060A (zh) | 2016-05-11 |
| MX2016003855A (es) | 2016-08-04 |
| PH12016500473A1 (en) | 2016-05-16 |
| CA2925281A1 (en) | 2015-04-02 |
| EP4091629A1 (en) | 2022-11-23 |
| RU2016110430A (ru) | 2017-10-30 |
| BR112016006192A2 (pt) | 2017-09-26 |
| CA2925281C (en) | 2022-05-03 |
| HK1225645A1 (zh) | 2017-09-15 |
| KR20160046879A (ko) | 2016-04-29 |
| KR102319843B1 (ko) | 2021-10-29 |
| WO2015048115A1 (en) | 2015-04-02 |
| KR20180041245A (ko) | 2018-04-23 |
| RU2662685C2 (ru) | 2018-07-26 |
| JP2019206541A (ja) | 2019-12-05 |
| MX373669B (es) | 2020-04-02 |
| EP3049106A1 (en) | 2016-08-03 |
| PH12016500473B1 (en) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6821429B2 (ja) | Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法 | |
| US11154609B2 (en) | PCV/mycoplasma hyopneumoniae vaccine | |
| US9650601B2 (en) | PCV/mycoplasma hyopneumoniae/PRRS combination vaccine | |
| US20170209560A1 (en) | Mycoplasma hyopneumoniae vaccine | |
| US11013796B2 (en) | Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom | |
| HK40078311A (en) | Pcv2b divergent vaccine composition and methods of use | |
| HK40010885A (en) | Pcv/mycoplasma hyopneumoniae combination vaccine | |
| HK1206609B (en) | Pcv/mycoplasma hyopneumoniae combination vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170908 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170908 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180604 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181205 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190708 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190708 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20190719 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190822 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190823 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20191004 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20191008 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200409 |
|
| C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20200722 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200824 |
|
| C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20200824 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201116 |
|
| C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20201120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201124 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201201 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210104 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210106 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6821429 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |